
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is a pharmaceutical company that focuses on developing precision medicines through its proprietary and complementary technology platforms, targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company's key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. With its clinical pipeline, the company has a positive outlook for its PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007 programs. The recent approval and market exclusivity granted to its product Papzimeos in the treatment of adult recurrent respiratory papillomatosis (RRP) in the US market until August 2032, along with its strong launch and sales trajectory, reinforces the company's potential and ability to dominate this niche area. Precigen's cash flow breakeven by the end of 2026 also shows the company's financial stability, further supporting its positive outlook for investors.
Bears say
Precigen is actively pursuing label expansion opportunities through ongoing clinical trials, with management expecting that updated data from the Papzimeos pivotal trial at ASCO will support this. Additionally, the upcoming RRP Awareness Day in June, the first since PAPZIMEOS approval, is seen as a key opportunity to drive awareness and education of the product. Despite lowering the discount rate, the company is projecting a significant decline in its revenues and profits by 2027, likely due to increased competition in the immuno-oncology market and slower-than-expected adoption of its products.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares